MaaT Pharma Secures Funding Agreement with the EIB
MaaT Pharma has announced the receipt of funds to support its clinical development programs, following recent agreements with the European Investment Bank and Clinigen.
Initial Funding and Financial Overview
According to the press release, MaaT Pharma received an initial payment of 10.5 million euros in July 2025 under an exclusive licensing agreement with Clinigen. Additionally, in October 2025, the company successfully drew 3.5 million euros from Tranche A of a 37.5 million euro financing provided by the European Investment Bank (EIB). The company's cash and cash equivalents stood at 22.4 million euros as of September 30, 2025, covering financial needs until the end of February 2026.
Potential Additional Funding and Warrant Issuance
The agreement with Clinigen could enable MaaT Pharma to receive up to an additional 18 million euros, with 12 million linked to regulatory approvals and 6 million to commercial milestones. Concurrently, the issuance of 468,772 warrants to the EIB was completed as part of the financing. The exercise price is set at 4.5898 euros, and the loan is repayable over two years following a four-year deferment, with an annual interest rate of 7%.
Innovative Company Status and Financial Performance
In September 2025, MaaT Pharma was awarded the 'Innovative Company' label by Bpifrance, highlighting its growth potential in the biotechnology sector. The company recorded a revenue of 3.4 million euros for the first nine months of 2025, representing a 45% increase compared to the same period in 2024. MaaT Pharma continues to focus on the development of its gut microbiome-based therapies to enhance the survival of cancer patients.
